Abstract
Aspirin (ASA) is unique among current therapies because it acetylates cyclooxygenase (COX)-2 enabling the biosynthesis of R-containing precursors of endogenous antiinflammatory mediators. Here, we report that lipidomic analysis of exudates obtained in the resolution phase from mice treated with ASA and docosahexaenoic acid (DHA) (C22:6) produce a novel family of bioactive 17R-hydroxy-containing di- and tri-hydroxy-docosanoids termed resolvins. Murine brain treated with aspirin produced endogenous 17R-hydroxydocosahexaenoic acid as did human microglial cells. Human COX-2 converted DHA to 13-hydroxy-DHA that switched with ASA to 17R-HDHA that also proved a major route in hypoxic endothelial cells. Human neutrophils transformed COX-2-ASA–derived 17R-hydroxy-DHA into two sets of novel di- and trihydroxy products; one initiated via oxygenation at carbon 7 and the other at carbon 4. These compounds inhibited (IC50 ∼50 pM) microglial cell cytokine expression and in vivo dermal inflammation and peritonitis at ng doses, reducing 40–80% leukocytic exudates. These results indicate that exudates, vascular, leukocytes and neural cells treated with aspirin convert DHA to novel 17R-hydroxy series of docosanoids that are potent regulators. These biosynthetic pathways utilize omega-3 DHA and EPA during multicellular events in resolution to produce a family of protective compounds, i.e., resolvins, that enhance proresolution status.
References
59
Referenced
1,370
10.1073/pnas.92.21.9475
/ Proc. Natl. Acad. Sci. USA. (1995)10.1084/jem.192.8.1197
/ J. Exp. Med. (2000){'key': '2023072511474396800_BIB3'}
10.1126/science.2820055
/ Science. (1987){'key': '2023072511474396800_BIB5'}
10.1074/jbc.R100030200
/ J. Biol. Chem. (2001){'key': '2023072511474396800_BIB7'}
{'key': '2023072511474396800_BIB8'}
10.1172/JCI13375
/ J. Clin. Invest. (2001)10.1038/89759
/ Nat. Immunol. (2001)10.1016/S0165-6147(00)01771-5
/ Trends Pharmacol. Sci. (2001)10.4049/jimmunol.164.2.1029
/ J. Immunol. (2000)10.1073/pnas.052533799
/ Proc. Natl. Acad. Sci. USA. (2002)10.1055/s-0038-1655943
/ Thromb. Haemost. (1997){'key': '2023072511474396800_BIB15'}
{'key': '2023072511474396800_BIB16', 'first-page': '1213', 'volume': '351', 'year': '1998', 'journal-title': 'Lancet.'}
/ Lancet. (1998)10.1001/jama.287.2.203
/ JAMA. (2002)10.1056/NEJMoa012918
/ N. Engl. J. Med. (2002)10.1073/pnas.97.18.10197
/ Proc. Natl. Acad. Sci. USA. (2000)10.1016/S0140-6736(99)07072-5
/ Lancet (1999)10.1161/01.CIR.0000014682.14181.F2
/ Circulation. (2002)10.1016/0014-2999(95)00861-6
/ Eur. J. Pharmacol. (1996){'key': '2023072511474396800_BIB23', 'first-page': '46', 'volume': '286', 'year': '2002', 'journal-title': 'Sci. Am.'}
/ Sci. Am. (2002)10.1258/0007142001903535
/ Br. Med. Bull. (2000){'key': '2023072511474396800_BIB25'}
10.1074/jbc.275.9.6586
/ J. Biol. Chem. (2000)10.1038/9550
/ Nat. Med. (1999)10.1139/y93-103
/ Can. J. Physiol. Pharmacol. (1993){'key': '2023072511474396800_BIB29'}
10.1016/S0006-291X(84)80193-X
/ Biochem. Biophys. Res. Commun. (1984)10.1172/JCI111612
/ J. Clin. Invest. (1984)10.1021/ac00298a016
/ Anal. Chem. (1986)10.1074/jbc.M002863200
/ J. Biol. Chem. (2000)10.1172/JCI116601
/ J. Clin. Invest. (1993)10.1006/prep.1996.0003
/ Protein Expres. Purif. (1996){'key': '2023072511474396800_BIB36'}
10.1021/bi00044a041
/ Biochemistry. (1995){'key': '2023072511474396800_BIB38', 'first-page': '2736', 'volume': '15', 'year': '2001', 'journal-title': 'FASEB J.'}
/ FASEB J. (2001){'key': '2023072511474396800_BIB39'}
10.1046/j.1471-4159.1994.62062437.x
/ J. Neurochem. (1994)10.1111/1523-1747.ep12515911
/ J. Invest. Dermatol. (1991)10.1021/bi962476u
/ Biochemistry. (1997)10.1073/pnas.80.12.3581
/ Proc. Natl. Acad. Sci. USA. (1983)10.1073/pnas.89.11.4888
/ Proc. Natl. Acad. Sci. USA. (1992)10.1074/jbc.272.1.601
/ J. Biol. Chem. (1997)10.1073/pnas.81.3.689
/ Proc. Natl. Acad. Sci. USA. (1984)10.1093/ajcn/71.1.361S
/ Am. J. Clin. Nutr. (2000)10.1080/07315724.1999.10718888
/ J. Am. Coll. Nutr. (1999)10.1073/pnas.93.1.49
/ Proc. Natl. Acad. Sci. USA. (1996)10.1007/BF02535694
/ Lipids. (1986)10.1016/0028-3908(96)00127-X
/ Neuropharmacology. (1996)10.1126/science.290.5499.2140
/ Science. (2000)10.1152/japplphysiol.00927.2001
/ J. Appl. Physiol. (2002)10.1021/bi992000l
/ Biochemistry. (2000){'key': '2023072511474396800_BIB55'}
10.1073/pnas.071052598
/ Proc. Natl. Acad. Sci. USA. (2001)10.1001/jama.286.10.1187
/ JAMA. (2001)10.1056/NEJM200204113461502
/ N. Engl. J. Med. (2002)10.1084/jem.183.1.137
/ J. Exp. Med. (1996)
Dates
Type | When |
---|---|
Created | 22 years, 10 months ago (Oct. 21, 2002, 3:24 p.m.) |
Deposited | 1 year, 7 months ago (Jan. 7, 2024, 10:23 a.m.) |
Indexed | 2 days, 17 hours ago (Sept. 3, 2025, 7:09 a.m.) |
Issued | 22 years, 10 months ago (Oct. 21, 2002) |
Published | 22 years, 10 months ago (Oct. 21, 2002) |
Published Online | 22 years, 10 months ago (Oct. 21, 2002) |
Published Print | 22 years, 10 months ago (Oct. 21, 2002) |
@article{Serhan_2002, title={Resolvins}, volume={196}, ISSN={0022-1007}, url={http://dx.doi.org/10.1084/jem.20020760}, DOI={10.1084/jem.20020760}, number={8}, journal={The Journal of Experimental Medicine}, publisher={Rockefeller University Press}, author={Serhan, Charles N. and Hong, Song and Gronert, Karsten and Colgan, Sean P. and Devchand, Pallavi R. and Mirick, Gudrun and Moussignac, Rose-Laure}, year={2002}, month=oct, pages={1025–1037} }